African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2288

Full Length Research Paper

Synthesis of 2-(benzylthio)benzimidazole, 2-[(benzimidazol-2-yl)methylthio]benzimidazole and structural analogues against Haemoncus contortus

Sagne Jacques Akpa
  • Sagne Jacques Akpa
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar
Martial Venance Say
  • Martial Venance Say
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar
Roger Simplice Pepin Zoakouma*
  • Roger Simplice Pepin Zoakouma*
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar
Bamba Fante
  • Bamba Fante
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar
Drissa Sissouma
  • Drissa Sissouma
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar
Ane Adjou
  • Ane Adjou
  • Laboratoire de Chimie Organique et de Substances Naturelles (LCOSN), UFR SSMT, Université Félix Houphouët Boigny, 22 B.P 582 Abidjan 22, République de Côte d’Ivoire.
  • Search for this author on:
  • Google Scholar


  •  Received: 08 March 2016
  •  Accepted: 04 July 2016
  •  Published: 08 September 2016

 ABSTRACT

The coupling of the derivatives of the 2-mercaptobenzimidazole 1 with the derivatives of the (chloromethyl)benzene 2 gives 2-(benzylthio)benzimidazole 4a-k on the one hand, and with the 2-(chlorométhyl)benzimidazole 3 on the other the 2-(benzimidazolyl methylthio) benzimidazole and analogues 5a-k. We determined the structures of all synthesized compounds by Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS). The evaluation of the anthelmintic activities of these molecules on Haemonchus contortus showed that the introduction of the nitro group (NO2) in the structure causes a significant increase of the activity. Among the molecules evaluated in vitro for their anti-infectious activity, the compounds 4b, 5d, 5e, 5f and 5h revealed an activity which is comparable to that of the reference molecules (ivermectin and fenbendazole).

Key  words: 2-mercaptobenzimidazole, (chloromethyl)benzene, 2-(chloromethyl) benzimidazole, 2-(methylthio) benzimidazole,  2-(benzylthio)benzimidazole, 2-(benzimidazolyl methylthio)  benzimidazole, anthelmintic, Haemonchus contortus.


 INTRODUCTION

Intestinal parasitic are very spread infections throughout the world and most of them are rampant in tropical areas mainly in developing countries where all favorable factors for their hatching are gathered: Hot and humid climate, lack or inadequacy of hygiene and sanitization measures and poverty. Although the consequences of the different pathologies are minor in developed countries, they are cruelly dramatic in poor or developing countries. These parasitic ailments are public health issues and are responsible for high rates of morbidity and mortality.

Gastrointestinal nematode infections are major pathologies in both human beings and animals. In sheep farming, this parasitism may be a limiting factor in the production because controlling it requires implementing medicinal measures as well as the implementation of sanitary measures. This curse causes huge economic losses in food-processing (Hussain and Dawson, 2013; Roeber et al., 2013). Several studies worldwide permitted to identify different species of nematodes and it is to be noticed  that  the  most  common  nematode  veterinarian and the most dangerous is the species Haemonchus contortus (Achi and Zinsstag, 2003; Tehrani et al., 2012). Now, the fight against parasitic diseases rests on the use of molecules containing in their skeleton the benzimidazole. This nucleus is the pharmacophore of many drugs used in therapeutics, namely in the treatment of infectious diseases. In the chemotherapy of intestinal helminthiasis, the most determining discovery is with no doubt the one relating to the biologically active chemical class of compounds, which the most contain the benzimidazole ring in the skeleton such as the thiabendazole, the albendazole , the mebendazole and the flubendazole (Figure 1) which are common use drugs against intestinal worms. However, in veterinary medicine, the most effective means of fight remains the use of anthelmintic drugs whose representative is currently the triclabendazole (Figure 1) which is the most used (Fairweather, 2009). According to its uniqueness, several pharmacochemical investigations about its chemical profile were carried out to extend its spectrum of activity (Mahiuddin et al., 2007; Anelia and al., 2006). But, this chemotherapy shows its limits with the emergence of various strains resisting to many of these drugs (Kaplan, 2004; Fairweather, 2009; Olaechea et al., 2011; Winkelhagen et al., 2012; Van den Brom et al., 2013; Saunders and al, 2013; Ortiz and al., 2013; Brockwell et al., 2014).

 

 

In this context, it seems important for us to synthesize new agents with nematicide aims, particularly active on H. contortus. To reach our objectives, we carried out an arranged structural variation thanks to the substitute flexibility of positions -2 and -5 of the 2-méthylthiobenzimidazole, basic structure of the triclabendazole. Through a rational analysis of the correlations structure-activity and the perspectives of the requirements of pharmacochemistry, we applied a technique of pharmaco-modulation on the pseudo typical molecule from the basic benzimidazole skeleton by replacing the methylthio group by the methylthioaryl or methylthioheteroaryl group. This replication by molecular rearrangement allows understanding that the chemical arrangement related to the specific structural modification is able to allow improving the molecular environment in order to optimize the pharmacological action or a modulation of the biological activity.

We tested on H. contortus these new anthelmintic candidates drugs, stemming from these molecular reorganizations, structural analogues of the triclabendazole, in order to assess their nematocide activities.

 

 

 


 MATERIALS AND METHODS

Chemistry

General

Melting points were determined using a  Kofler  benchto  graduating temperature (40-206°C). Purifications by column chromatography were carried out on Kieselgel 60 (230-400 mesh, Merck).1H and 13C measured on a 300 MHz Bruker Avanced apparatus with tetramethylsilane (TMS) served as internal standard: The NMR spectra (1H and 13C) were performed in DMSO. Mass spectra were conducted on a HP5889A spectrometer. All spectrometers analysis was realized in the CEISAM laboratory of the University of Nantes.

General procedure for synthesis of compounds 4a-k: Initially, we prepared 2-mercaptobenzimidazole derivatives 1 (Van Allan and Deacon, 1963) from reaction of o-phenylene diamine with carbon disulfide in DMF. Then, to 1 g of compound 1 dissolved in 10 mL of anhydrous ethanol added 1.2 equivalent of (chloromethyl) benzene(derivatives 2 (Scheme 1). The mixture was refluxed for 2 h. The reaction medium was then neutralized with a solution of potassium bicarbonate (5%). The resulting precipitate 4 was filtered off, washed up with cold ethanol and then purified by column chromatography on silica gel. Eluent: ethyl acetate/hexane: v/v : 30/70. Table 1 shows the physicochemical characteristics of compounds 4a-k.

 

 

 

Synthesis of 2-(benzylthio)-1H-benzimidazole 4a: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and chloromethyl) benzene (1.01 g, 7.99 mmol) 4a was obtained (1.41 g, 88%) as crystals; MP = 122-124°C.

1H NMR (DMSO, 300 MHz) d :4.57 (2H, s, S-CH2); 7.10-7.16 (2H, m, Har); 7.22-734 (2H, m, Har); 7.44-747 (3H, m, Har).

13C NMR (DMSO, 75 MHz) d: 35.12 (S-CH2); 114.08 (2 Car); 121.39 (2 Car); 127.27 (Car); 128.44 (2 Car); 128.80 (2 Car); 137.64 (Car); 149.66 (N=C-S).

Mass (m/z) = 240. M+ = 240.1 (5); M+1 = 241.1 (100); M+2 = 242.1 (17); m/z (%): 243.1 (8).

Synthesis of 2-(3-nitrobenzylthio)-1H-benzimidazole4b: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and 1-(chloromethyl)-3-nitrobenzene (1.37 g, 7.99 mmol), 4b was obtained (1.61 g, 85%) as crystals; MP = 216-218°C.

1H NMR (DMSO, 300 MHz) d : 4.70 (2H, s, S-CH2); 7.10-7.15 (2H, m, Har); 7.44-7.62 (3H, m, Har); 7.91-7.94 (2H, m, Har).

13C NMR (DMSO, 75 MHz) d :33.94 (S-CH2); 113.65 (2 Car); 121.47 (Car); 122.14 (2 Car); 123.50 (Car); 129.85 (Car); 135.53 (Car); 139.63 (2 Car); 140.68 (Car); 147.62 (N=C-S); 149.06 (C-NO2).

Mass (m/z) = 285. M+ = 285.10 (5); M+1 = 286.1 (100); M+2 = 287.1 (20); m/z (%): 288.1 (8).

Synthesis of 2-(4-chlorobenzylthio)-1H-benzimidazole4c: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and 1-chloro-4-(chloromethyl)benzene (1.29 g, 7.99 mmol), 4c was obtained (1.13 g, 62%) as crystals); MP = 181-182°C.

1H NMR (DMSO, 300 MHz) d: 4.60 (2H, s, S-CH2); 7.14-7.18 (2H, m, Har); 7.37-7.40 (2H, m, Har); 7.49-7.52 (4H, m, Har).

13C NMR (DMSO, 75 MHz) d : 35.20 (S-CH2); 114.91 (2 Car); 122.46 (2 Car); 129.30-129.62 (2 Car); 131.65-132.44 (2 Car); 132.89 (Car); 138.03 (Car); 140.34 (2 Car); 150.41 (N=C-S).

Mass (m/z) = 274. M+ = 274.94 (31.60); M+1 = 275,94 (31,60); m/z (%): 273.98 (77.84); 241.07 (24.85); 148.93 (17.16); 126.90 (30.98); 124.87 (100); 121.90 (21.31); 88.92 (23.59); 85.84 (12.52); 83.82 (15.63); 48.86 (19.66).

Synthesis of 2-(2,4-dichlorobenzylthio)-1H-benzimidazole4d: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and 2,4-dicholoro-1-(chloromethyl)benzene (1.56 g, 7.99 mmol), 4d was obtained (1.56 g, 76%) as crystals; MP = 157-158°C.

1H NMR (DMSO, 300 MHz) d: 4.68 (2H, s, SCH2); 7.16-7.18 (2H, m, Har); 7.37-7.39 (3H, m, Har); 7.50-7.52 (2H, m, Har).

13C NMR (DMSO, 75 MHz) d: 33.63 (S-CH2); 114.85 (Car); 122.43 (Car); 128.33 (Car); 129.50-129,80 (Car); 133.22 (Car); 133.91 (Car); 140.36 (Car); 149.75 (N=C-S).

Mass (m/z) = 309. M+ = 309.90 (27.24); m/z (%): 307.01 (41.82); 274.96 (38.40); 273 (15.67); 272.93 (100); 239.99 (14.68); 162.92 (12.04); 160.88 (41.75); 158.84 (67.05); 148.87 (15.77%); 122.93 (17.02); 121.91 (27.75); 88.93 (15.55).

Synthesis of 2-(benzylthio)-5-nitro-1H-benzimidazole 4e: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and (chloromethyl) benzene (0.78 g, 6.15 mmol), 4e was obtained (1.18 g, 81%) as crystals, MP = 162-163°C.

1H NMR (DMSO, 300 MHz) d: 4.63 (2H, s, S-CH2); 7.24-7.35 (3H, m , Har); 7.47-7.49 (2H, m, Har); 7.59-7.62 (1H, m, Har); 8.04-8.08 (1H, m, Har); 8.32- 8.33 (1H, m, Har);

13C NMR (DMSO, 75 MHz) d: 34.96 (S-CH2); 110.34 (Car); 113.25 (Car); 117.46 (Car); 127.45 (Car); 128.50 (2 Car); 128.91 (2 Car); 137.09 (2 Car); 142.13 (Car); 155.9 (N=C-S);

Mass (m/z) = 285. M+ = 285.32 (100); M+1 = 286.8 (13%); m/z (%): 284.9 (35%); 283 (20%); 281.3 (10%).

Synthesis of 5-nitro-2-(3-nitrobenzylthio)-1H-benzimidazole 4f: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and 1-(chloromethyl)-3-nitrobenzene (1.05 g, 6.15 mmol), 4f was obtained (1.27 g, 75%) as a crystals; MP = 210-211°C.

1H NMR (DMSO, 300 MHz) d: 4.76 (2H, s, S-CH2); 7.58-7.64 (2H, m, Har); 7.95-7.98 (1H, m, Har); 8.04-8.12 (2H, m, Har); 8.32 (1H, m, Har); 8.41 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 34.06 (S-CH2); 117.53 (2 Car); 122.29 (Car); 123.62 (Car); 129.91 (Car); 135.64 (Car); 140.13 (2 Car); 142.20 (Car); 147.65 (N=C-S); 155,37 (Car).

Mass (m/z) = 330. M+ = 330.32 (4); M+1 = 331 (100); M+2 = 332 (15).

Synthesis of 2-(4-chlorobenzylthio)-5-nitro-1H-benzimidale 4g: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and 1-chloro-4-(chloromethyl)benzene (1.00 g, 6.15 mmol), 4 g was obtained (1.39 g, 85%) as crystals; MP = 155-156°C.

1H NMR (DMSO, 300 MHz) d:4.61 (2H, s, S-CH2); 7.31-7.37 (2H, d, Har); 7.49-7.31 (3H, 3m, Har); 8.03-8.06 (1H, dd, Har); 8.31 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 33.60 (S-CH2); 114.4 (Car); 116.1 (Car); 118.6 (Car); 128.8-129.1 (4 Car); 137.7 (Car); 141.7 (Car); 147,1 (N=C-S).

Mass (m/z) = 319. M+ = 319 (5); M+1 = 320.96 (11.17); m/z (%) : 322.02 (2.08); 318.94 (28.89); 126.91 (32.10); 124.87 (100); 88.95 (16.91).

Synthesis of 2-(2,4-dichlorobenzylthio)-5-nitro-1H-benzimidale 4h: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and 2,4-dicholoro-1-(chloromethyl)benzene (1.20 g, 6.15 mmol), 4h was obtained (1.45 g, 80%) as crystals; MP = 98-100°C.

1H NMR (DMSO, 300 MHz) d: 4.72 (2H, s, S-CH2); 7.38-7.40 (2H, m, Har); 7.63-7.64 (1H, m, Har); 7.70-7.72 (1H, m, Har); 8.07-8.10 (1H, m, Har); 8.36 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 32.59 (S-CH2); 113.42 (Car); 117.51 (Car); 127.47 (Car);128.58-128.91 (2 Car); 131.37 (Car);133.51-134.25 (2 Car); 139.47 (Car); 140.32 (Car); 143.40 (Car); 155.07 (N=C-S).

Mass (m/z) = 354. M+ = 354.93 (21.66); m/z (%): 352.89 (29.52); 319.95 (31.20); 317.88 (84.95); 160.86 (65.31); 158.84 (100); 122.84 (16.13); 88.93 (11.21).

Synthesis of [2-(benzylthio)-1H-benzimidazole-5-yl][phenyl] méthanone 4i: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and (chloromethyl)benzene (0.60 g, 4.72 mmol), 4i was obtained (1.08 g, 90 %) as crystals; MP = 98-100°C. 1H NMR (DMSO, 300 MHz) d: 4.66 (2H, s, S-CH2); 7.28-7.36 (3H, m, Har); 7.49-7.70 (7H, m, Har); 7.76-7.81 (2H, m, Har); 7.87 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 36.00 (S-CH2); 114.42 (Car); 124.76

(Car), 128.31 (Car); 129.27-129.50 (2 Car); 129.80-130.27 (2 Car); 131.35-132.33 (2 Car); 132.62-132.88 (2 Car); 138.27 (Car); 139.06 (Car); 154.86 (Car); 167.50 (N=C-S); 196.45 (C=O).

Mass (m/z) = 344. M+ = 344.02 (55.85); M+1 = 345.08 (12.81); m/z (%) : 311.03 (27.23); 104.94 (10.52); 90.93 (100); 76.89 (12.99); 64.92 (10.55).

Synthesis of [2-(4-chlorobenzylthio)-1H-benzimidazol-5-yl][phényl]méthanone 4j: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and 1-chloro-4-(chloromethyl)benzene (0.76 g, 4.72 mmol), 4j was obtained (1.19 g, 80%) as crystals; MP = 98-100°C.

1H NMR (DMSO, 300 MHz) d: 4.59 (2H, s, S-CH2); 7.35-7.39 (2H, m, Har); 7.49-7.58 (5H, m, Har); 7.63-7.67 (1H, m, Har); 7.72-7.73 (2H ,m, Har); 7.74-7.75 (1H, m, Har); 7.81 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 35.03 (S-CH2); 114.59 (Car); 117.95 (Car); 123.32 (Car); 129.22-129.29 (2 Car); 130.25-131.692 (2 Car); 132.50-132.64 (2 Car); 138.71 (Car); 139.87 (Car); 143.17 (Car); 147.60 (Car); 157.88 (N=C-S); 196.73 (C=O).

Mass (m/z) = 378. M+ = 378 (34.18); M+2 = 380 (12.09); m/z (%): 345.00 (12.52); 126.9 (34.10); 126 (11.12); 124.9 (100); 104.9 (10.16); 88.9 (22.27); 76.9 (19.78).

Synthesis of [2-(2,4-dichlorobenzylthio)-1H-benzimidazole-5-

yl][phényl]méthanone 4k: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and 2,4-dichloro-1-(chloromethyl)benzene (0.92 g, 4.72 mmol), 4k was obtained (1.48 g, 91%) as crystals: MP = 110 -111°C.

1H NMR (DMSO, 300 MHz) d: 4.70 (2H, s, Har); 7.38-7.41 (1H, m, Har); 7.57-7.70 (5H, m, Har); 7.73-7.77 (2H, m, Har); 7. 86 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 33.62 (S-CH2); 114.67 (Car); 117.59 (Car); 125.00 (Car); 128.54 (Car); 129.43 (2 Car); 129.00-130.44 (4 Car); 131.51 (Car); 140.11 (Car); 143.57 (Car); 153.65 (Car); 167.95 (N=C-S); 196.58 (C=O).

Mass (m/z) = 413. M+ = 413 (10); M+1 = 414.17 (11.85); m/z (%) : 411.90 (23.62); 378.97 (37.21); 376158.95 (100); 344.01 (11.42); 197.98 (10.82); 160.14 (43.38); 87 (62.21); 122.88 (10.75); 105.08 (14.74); 85.90 (15.95); 83.80 (20.72); 76.87 (32.84); 48.89 (27.22).

 

General procedure for synthesis of compounds 5a-k

This preparation involved three steps (Scheme 2): First step include synthesis of 2-mercaptobenzimidazole derivatives and analogues 1 from reaction of o-phenylene diamine derivatives or analogues with carbon disulfide in DMF according to Van Allan method (Van Allan and Deacon, 1963). The second relates the formation of 2-(méthylthio)benzimidazole 3 by condensation of o-phenylene diamine with chloroacetic acid in hydrochloric acidmedium (Phillips, 1928). In the third step, to 1 g of compound 1 in 10 mL of anhydrous ethanol was added 1.5 equivalent of 2-(chloromethyl)benzimidazole(derivative) 3. The mixture was refluxed for 2 h. The reaction medium was then neutralized with a solution of sodium hydrogen carbonate (5%). The resulting precipitate 5 was filtered off, washed up with cold ethanol then purified by column chromatography on silica gel. Eluent : ethyl acetate/hexane : v/v : 80/20. Table 2 shows the physicochemical characteristics of compounds 5a-k.

 

 

 

Synthesis of 2-[(1H-benzimidazol-2-yl)méthylthio]-1H-benzimidazole 5a: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and 2-(chloromethyl)-1H-benzimidazole (1.66 g, 10 mmol) 5a was obtained (1.12 g, 60%) as crystals; MP = 253-256°C.

1H NMR (DMSO, 300 MHz) d: 4.80 (2H, s, S-CH2); 7.13-7.14 (4H, m, Har); 7.51 (4H, m, Har).

13C NMR (DMSO, 75 Hz) d: 28.86 (S-CH2); 121.56 (Car); 149.27

 (CH2-C=N); 150.51 (N=C-S).

Mass (m/z) = 280. M+ = 280 (7); M+1 = 281 (100); M+2 = 282.1 (20); m/z : 261.1 (25); 132.9 (61); 151 (69).

Synthesis of 2-[(1H-benzimidazol-2-ylthio)méthyl]-5-nitro-1H-benzimidazole 5b: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol)  and  2-(chloromethyl)-5-nitro-1H-benzimidazole  (2.11 g,  10 mmol), 5b was obtained (1.32 g, 61%) as a crystals; MP = 265-266°C.

1H NMR (DMSO, 300 MHz) d: 4.99 (2H, s, S-CH2); 7.24-7.27 (2H, m, Har); 7.53-7.60 (2H, m, Har); 7.67-7.70 (1H, m, Har); 8.11-8.13 (1H, m, Har); 8.47-8.48 (1H, m, Har).

13C NMR (DMSO, 75 Hz) d: 30.04 (S-CH2); 113.16 (Car); 114.89 (2 Car); 115.64 (Car); 123.52 (2 Car); 132.48-132.66 (2 Car); 143.27-143.62 (2 Car); 149.92 (CH2-C=N); 156.58 (Car); 167.92 (N=C-S).

Mass (m/z) = 325. M+ = 325.35 (42.61); M+1 = 326 (12.60); m/z (%) : 149.9 (100); 148.9 (23.30); 117 (10.39); 106 (11.39); 89.9 (10.72); 62.9 (14.44).

Synthesis of [2-((1H-benzimidazol-2-ylthio)méthyl)-1H-benzimidazol-5-yl][phényl]méthanone 5c: From 2-mercaptobenzimidazole (1.00 g, 6.66 mmol) and [2-(chloromethyl)-1H-benzimidazol-5-yl] [phenyl] methanone (2.70 g, 10 mmol), 5c was obtained (2.00 g, 78%) as crystals; MP = 190-191°C.

1H NMR (DMSO, 300 MHz) d: 4.89 (2H, s, S-CH2); 7.17-7.19 (2H, m, Har); 7.51-7.59 (4H, m, Har); 7.66-7.75 (5H, m, Har); 7.94 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 29.88 (S-CH2); 115.83 (Car); 119.06 (Car); 122.86 (Car); 125.18 (Car); 129.49-129.70 (2 Car); 132.17-132.55 (2 Car); 132.74 (Car); 133.21 (Car); 139.05-142.51 (3 Car); 150.06 (CH2-C=N); 154.87 (Car); 168.05 (N=C-S); 196.85 (C=O).

Mass (m/z) = 384. M+ = 384.03 (100); M+1 = 385.09 (26.67); m/z (%): 351.08 (35.20); 235.01 (35.74); 149.94 (27.33); 129.90 (20.76); 76.94 (15).

Synthesis of 2-[(1H-benzimidazol-2-yl)méthylthio]-5-nitro-1H-benzimidazole 5d: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and 2-chloromethyl-1H-benzimidazole (1.28 g, 7.68 mmol), 5d was obtained (1.18 g, 71%) as crystals; MP = 247-248°C.

1H NMR (DMSO, 300 MHz) d: 4.88 (2H, s, S-CH2); 7.14-7.19 (2H,
dd, Har);  7.50-7.55 ( 2H, dd, Har);  7.62-7.65 (1H, d, Har);   8.06-8.09

(1H, dd, Har); 8.37-8.38 (1H, m, Har).

13C NMR (DMSO, 75 MHz) d: 28.76 (S-CH2); 113.45 (Car); 115.03 (Car); 117.55 (Car); 121.84 (Car); 139.02 (Car); 142.21 (CH2-C=N); 150.03 (Car); 155.47 (N=C-S).

Mass (m/z) = 325. M+ = 325 (4); M+1 = 326 (100); M+2 = 327.2 (22); m/e (%) : 196 (10); 166 (11); 133 (37); 132 (11).

Synthesis of 5-nitro-2-[(5-nitro-1H-benzimidazol-2-yl)méthylthio]-1H-benzimidazole 5e: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and 2-chloromethyl-5-nitro-1H-benzimidazole (1.63 g, 7.68 mmol), 5e was obtained (1.00 g, 53%) as crystals; MP = 180-181°C.

1H NMR (DMSO, 300 MHz) d: 4.97 (2H, s, S-CH2); 7.64-7.75 (2H, m, Har); 8.08-8.12 (2H, m, Har); 8.39-8.47 (2H, m, Har).

13C (DMSO, 75 MHz) d: 28.64 (S-CH2); 117.58 (Car); 128.59 (Car); 142.21 (CH2-C=N); 142.55 (Car); 155.37 (N=C-S).

Mass (m/z) = 370. M+ = 370 (19.54); m/z (%): 194.9 (100); 164.9 (37.26); 148.9 (57.42); 136.9 (21.72); 121.9 (30.48); 89.9 (46.08); 104.9 (46.15); 62.2 (61.52).

 

Synthesis of [2-((5-nitro-1H-benzimidazol-2ylthio)méthyl)1H-benzimidazol-5-yl][phényl]méthanone 5f: From 5-nitro-2-mercaptobenzimidazole (1.00 g, 5.12 mmol) and [2-(chloromethyl)-1H-benzimidazol-5-yl] [phenyl] methanone (2.08 g, 7.68 mmol), 5f was obtained (1.58 g, 72%) as crystals; MP = 161-162°C.

1H NMR (DMSO, 300 MHz) d: 4.98 (2H, s, S-CH2); 7.55-7.59 (2H, m, Har); 7.65-7.76 (6H, m, Har); 7.95-7.96 (1H, m, Har); 8.08-8.11 (1H, dd, Har); 8.39 (1H, d, Har).

13C NMR (DMSO, 75 MHz) d: 29.59 (S-CH2); 111.59 (Car); 114.41 (Car); 115.69 (Car); 118.50 (Car); 118.92 (Car); 125.01 (Car); 129.28-129.53 (2 Car); 130.32 (2 Car); 132.62-132.97 (Car); 138.93 (Car); 140.50 (CH2-C=N); 142.34-144.46 (Car); 156.12 (Car); 167.81 (N=C-S); 196.51 (C=O).

Mass (m/z) = 429. M+ = 429.87 (30.59); m/z (%) : 428.97 (100); 396.14  (21.54);  236.06  (51.34);  235.03  (96.31);  148.95  (55.25); 129.99 (44.82); 105.62 (43.28); 76.94 (49.60).

Synthesis of [2-((1H-benzimidazol-2yl)méthylthio)-1H-benzimidazol-5-yl][phényl]méthanone 5g: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and 2-(chloromethyl)-1H-benzimidazole (0.98 g, 5.90 mmol), 5g was obtained (1.30 g, 86%) as crystals; MP = 255-256°C.

1H NMR (DMSO, 300 MHz) d: 4.91 (2H, s, S-CH2,); 7.17-7.21 (2H, dd, Har); 7.54-7.61 (4H, m, Har); 7.64-7.7 (4H, m, Har); 7.73-7.78 (1H, m, Har); 7.91 (1H, m, Har).

13C (DMSO, 75 MHz) d: 29.77 (S-CH2); 116.00 (3 Car); 122.89 (Car); 124.91 (Car); 129.40 (Car); 129.64 (2 Car); 130.43 (2 Car); 131.43 (Car); 132.48 (Car); 132.66 (3 Car); 139.95 (Car); 151.32 (CH2-C=N); 153.97 (Car); 167.91 (N=C-S); 196.57 (C=O).

Mass (m/z) = 384. M+ = 384.04 (58.75); M+1 = 385.08 (16.21); m/z (%) : 253.99 (71.46); 176.91 (62.42); 131.99 (56.79); 130.07 (100); 76.88 (52.35).

Synthesis of [2-((5-nitro-1H-benzimidazol-2yl)méthylthio)-1H-benzimidazol-5-yl][phényl]méthanone 5h: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and 2-(chloromethyl)-5-nitro-1H-benzimidazole (1.25 g, 5.90 mmol), 5h was obtained (1.42 g, 84%) as crystals; MP = 93-94 °C.

1H NMR (DMSO, 300 MHz) d: 4.96 (2H, s, S-CH2,); 7.60 (2H ,m, Har); 7.65-7.70 (5H, m, Har); 7.89 (1H, m, Har); 8.10-8.13 (1H, dd, Har); 8.47-8.48 (1H, d, Har).

13C (DMSO, 75 MHz) d: 29.70 (S-CH2); 113.64-118.73 (3 Car); 124.94 (Car); 129.63 (Car); 130.42 (2 Car); 131.49 (2 Car); 132.47 (Car); 132.66 (Car); 133.06 (Car); 139.04 (Car); 143.53 (CH2-C=N); 153.59 (Car); 156.73 (Car); 167.92 (N=C-S); 196,55 (C=O).

Mass (m/z) = 429. M+ = 429.01 (56.19); m/z (%) : 253.00 (78.44); 176.94 (100); 129.9 (25.66); 104.94 (26.51); 76.92 (31.40).

[2-((5-benzoyl-1H-benzimidazol-2yl)méthylthio)-1H-benzimidazol-5-yl][phényl]méthanone 5i: From (2-mercaptobenzimidazol-5-yl) (phenyl) methanone (1.00 g, 3.93 mmol) and [2-(chloromethyl)-1H-benzimidazol-5-yl] [phenyl] methanone (1.60 g, 5.90 mmol), 5i was obtained (1.00 g, 52%) as crystals; MP = 150-154°C.

1H NMR (DMSO, 300 MHz) d: 4.95 (2H, s, S-CH2); 7.55-7.60 (4H, m, Har); 7.66-7.69 (6H, m, Har); 7.90 (2H, m, Har); 7.95 (2H, m, Har).

13C (DMSO, 75 MHz) d: 29.73 (S-CH2); 124.81 (Car); 129.26 (4 Car);130.30 (4 Car); 131.45 (Car); 131.82 (2 Car);132.91 (Car); 139.01 (Car); 154.46 (N=C-S); 196.44-196.55 (2 C=O).

Mass (m/z) = 488. M+ = 488.10 (71.89); m/z (%) : 253.91 (53.38); 234.94 (72.20); 176.90 (22.37); 158.90 (33.46); 129.94 (31.15); 104.92 (85.89); 76.86 (100).

Synthesis of 2-[(1H-benzimidazole-2yl)methylthio]benzothiazol 5j: From 2-mercaptobenzothiazole (1.00 g, 5.98 mmol) and 2-(chloromethyl)benzimidazole (1.49 g, 8.97 mmol), 5d was obtained (0.96 g ,54%) as crystals; MP = 176-177°C.

1H NMR (DMSO, 300 MHz) d: 4.90 (2H, s, S-CH2); 7.15-7.19 (2H, m, Har); 7.34-7.59 (4H, m, H); 7.59-7.91 (1H, m, Har); 8.01-8.04 (1H, m, Har).

13C (DMSO, 75 MHz) d: 30.31 (S-CH2); 121.25 (2 Car); 121.86 (2 Car); 124.56 (Car); 126.39 (Car); 134.79 (2 Car); 149.53 (CH2-C=N); 152.47 (Car); 165.59 (N=C-S).

Synthesis of synthesis of 2-[(1H-benzimidazole-2yl)methylthio]-6-methylbenzoxazole 5k: From 5-methyl-2-mercaptobenzoxazole (1.00 g, 6.05 mmol) and 2-(chloromethyl)-1H-benzimidazole (1.51 g, 9.08 mmol), 5k was obtained (0.91 g, 51%) as a crystals; MP = 181-182°C.

1H NMR (DMSO, 300 MHz) d: 2.42 (3H, s, CH3); 4.85 (2H, s, S-CH2); 7.15-7.19 (3H, m, Har); 7.48-7.54 (4H, m, Har).

13C  (DMSO,  75 MHz)  d:   21.07   (CH3);   29.40   (S-CH2);   162.42  (N=C-S); 151.65 (Car); 149.40 (CH2-C=N); 139.01 (Car); 134.36 (Car); 125.6 (Car); 121.86 (2 Car); 117.76 (Car); 110.33 (Car).

Mass (m/z) = 295. M+ = 295 (5); M+1 = 296.1 (100); M+2 = 297.1 (20).

 

Anthelmintics activities

The nematocide test used is an enhancement of the method initially described by Diehl et al. (2004). This required prior a reasonable number of 3000 eggs of H. contortus obtained by experimental infection of breeding sheep. Compounds 4a-k and 5a-k and the anthelmintic drugs (fenbendazole and ivermectin) (7.5 mg per sample) were dissolved in 1 mL of DMSO and diluted with distilled water to obtain a dilution series in 96 well of microtiter plates. Some agar (l40 μL, 45-50°C) containing 2% of amphotericin B was added to each well with also 80 of Haemonchus eggs. The plates were maintained at 27°C in a humid atmosphere (90%) for 6 days. The normal development of larvae without products on trial was also carried in wells containing distilled water to serve as control to the experiment. The number of hatched eggs and the number of larvae was counted the stages of development and the mobility of larvae was recorded. For a development rate between 0 and 5%, the test molecule was considered as an active one. The tests were carried out repeatedly three times with all compounds showing a nematocide activity.

 

 

 


 RESULTS

Chemical results

We synthesized and isolated 22 molecules carrying both benzimidazole and methylthio moiety in their structure. These compounds, structural analogues of triclabendazole was obtained by total synthesis with a yield varying between 51 and 91% and divided in three series (Figure 2).

 

 

The 2-(benzylthio) benzimidazole derivatives 4a-k (Table 1), the 2-(benzimidazolyl methylthio) benzimidazole derivatives 5a-i (Table 2) and their analogues 2-(benzimidazolyl methylthio) benzothiazole 5j and 2-(benzimidazolyl methylthio) benzoxazole 5k (Table 2). Moreover, benzene ring in the first two series carried various modulators such us nitro (NO2), benzoyl (PhCO) and chloro (Cl).

The spectroscopic proton NMR characterization (Table 1) of all synthesized compounds showed one characteristic peak between 2.42 and 4.99 ppm corresponding to the chemical shift of the proton S-CH2-. Concerning 13C spectra, we noted two main peaks: From 28.64 to 36.00 ppm for S-CH2- and from 140.50 to 167.95 ppm for N=C-S. The molecular peaks in mass spectrometry of these methylthio benzimidazoles (Table 1) varied between 240 and 488 depending on their substituents.

 

Anti-Haemonchus activities

 

Regarding nematocidal activities of synthesized compounds 4a-k and 5a-k (Table 3), the antiparasitic gm / mL) and 5d (CL100 = 0.002 gm / mL) had respectively a nematicidal activity in the same magnitude order as that of the reference molecules fenbendazole (CL100 = 0.0005 mg/mL) and ivermectin (CL100 = 0.009 mg/mL). Compounds 5e (CL100 = 0.68 mg/mL), 5f (CL100 = 0.68 mg/mL) and 5h(CL100 = 0.038 mg/mL) had lower activity than that of the reference product. 4a, 4f, 4g, 4h and 4k had very high larvicidal concentrations (CL100 = 2.86 mg/mL) compared to the reference molecules. Larvicidal concentration (CL100) was the lowest concentration for which the normal larval development was completely blocked (non-hatching eggs, paralysis or death of larvae).

 

 


 DISCUSSION

Analysis of the results of nematicide activities against H. contortus in connection with the structural changes made in the series of 2-(benzylthio) benzimidazole derivatives 4a-k (Table 1) allowed to  make the following observations.

First, presence of benzyl group on the 2-mercapto-benzimidazole (entity (A), (Figure 3) engendered the appearance of nematicide activities. The substitutions on this nucleus caused changes of activity. 

Also, when benzyl ring carried a nitro group (NO2) in the isomeric position-3, an increase of helminthicide activity was observed. Indeed, the product 4b (CL100 = 0.0005 μg/mL) was nearly 6000 times more active than the unsubstituted derivative 4a (CL100 = 2.86 μg/mL). In addition, compared to the reference nematicide molecules, the product 4b was 18 times more effective than ivermectin (CL100 = 0.009 mg/mL) and had an activity equivalent to that of fenbendazole (CL100 = 0.0005 mg/mL). The presence of halogenated entities on the benzene ring namely chlorine, induced a decrease of the nematocidal activity. Thus, para-chloro derivative 4c had a larvicidal activity (CL100 = 12.03 μg/mL) less than that of 4a and introducing two chlorines on the benzene ring (compound 4d) caused the disappearance of the activity (LC100 = 424 μg/mL).

 

 

Secondly, the introduction of a substituent such as nitro on the benzimidazole ring in position-5 produced a decrease in the activity. So, compound 4f had a larvicidal concentration (CL100 = 2.86 μg/mL) 5720 higher than that of compound 4b. The different substitutions made did not cause an improvement of this activity, it is the case of chloro isomer 4g (CL100 = 2.86 μg/mL) and 2,4-dichloro 4h (CL100 = 2.86 μg/mL) which had their activity equal to that of compound 4f; these had their activity four times greater than that of the non-nitrated derivative 4c (CL100 = 12.03 μg/mL). However, none of these substituted isomers at position-5 of benzimidazole by nitro group had larvicidal activity comparable to those of fenbendazole and ivermectin.                        

Thirdly, replacing the nitro groupat position-5 by another group such as benzoyl led to the loss of nematicide activity. Nevertheless, only one compound of this series seemed to have a larvicidal activity, the 4k (CL100 = 2.86 μg/mL) compared to 4a.

As for the obtained results after evaluating the nematicide activity of 2-(benzimidazolyl methylthio) benzimidazole derivatives 5a-k (Table 2) and their analogues allowed to make some interpretations.

First, replacing benzene moiety by benzimidazolyl inhibited the nematocidal activity. The product 5a (CL100 = 424 μg/mL) had larvicidal concentration 18 times greater than that induced by the benzyl derivative 4b (CL100 = 0.0005 μg/mL). The double substitution on the benzene homocycle (B) using substituents such as nitro (5b: CL100 = 424 μg/mL) and benzoyl (5c: CL100 = 424 μg/mL) had no effect on the nematicide activity compared to compound 4a (CL100 = 2.86 μg/mL).

Secondly, introducing a nitro group at position-5 of the 2-methylthiobenzimidazole on the entity (A) of compound 5a caused an enhancement of the activity. Thus, the larvicide product concentration 5d (CL100 = 0.002 μg/mL) obtained was multiplied by a factor of 212,000. It also showed an anti-Haemonchus which was 4 times lower respectively than those of fenbendazole and ivermectin. However, the introduction of substituents on the benzene homocyle (B) such as nitro and benzoyl decreased the activities.So, compounds 5e and 5f (CL100 = 0.68 μg/mL) were 340 times less active than the unsubstituted derivative 5d. Their activities however were greater than that of the unsubstituted derivatives on the entity (A). These compounds possessed nematocidal activity 623 times greater than that of 5a.

Thirdly, the replacement of nitro on the compound 5b of the entity (A) by a benzoyl group 5g (CL100 = 12.03 μg/mL) appeared to inhibit the nematocidal activity and it was 35 times more active than the unsubstituted derivative 5a. However, this larvicidal concentration remained significantly higher than those of ivermectin (CL100 = 0.009 μg/mL) and fenbendazole (CL100 = 0.0005 μg/mL). When homocycle entity (B) 5g was substituted in its position-5 by nitro group 5h (CL100 = 0.038 μg/mL), there was an increase of the larvicidal activity. This was 316 times greater than 5g. Compound 5h showed an anti-Haemonchus efficiency respectively 76 times and 4 times less than that of fenbendazole and ivermectin. The presence in the same position of the benzoyl 5i (LC100 = 424 μg/mL) caused the greatest loss of larvicidal activity. In this series, a third substitution has been carried out. This was the replacement of the benzimidazole ring of the entity (A) by benzothiazole 5j and benzoxazole 5k. This homology replication resulted in slight improvement in the nematicide activity compared to compound 5a.The larvicide concentration was divided by a factor 2 (5d) and 35 (5k). These activities remained very low compared to the reference compounds. A comparison of compounds 5j and 5k showed that the benzoxazole derivative exhibit anti-Haemonchus activity 18 times greater than its analogue benzothiazole.

 

 


 CONCLUSION

The syntheses carried out around the chemical series of 2-mercaptobenzimidazole allowed to obtain new compounds, derivatives and structural analogues of 2 (methylthio) benzimidazole which have been characterized by NMR (1H and13C) and mass spectroscopy. In vitro nematocide assays against H. contortus of the synthesized compounds revealed the anthelmintic activities of compounds 4b, 5d, 5e, 5f and 5h. Among them, 4b and 5d were active compared to fenbendazole or ivermectin. The structure-activity relationship study showed that coupling a benzene group with the methylthio group of 2-mercaptobenzimidazole was more advantageous to the appearance of nematocidal activities than that of a benzimidazole. In addition, the introduction of nitro (NO2) group on the benzene ring was favorable to an increase of nematicide activities.

 


 CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.


 ACKNOWLEDGMENTS

The authors thank the Swiss Centre for Scientific Research (CSRS) in Côte d’Ivoire for supporting them to the realization of our anthelmintic tests. Also thanks to the CEISAM laboratory of the University of Nantes for the chemical reagents and the spectroscopic analysis materials.



 REFERENCES

Achi YL, Zinsstag J, Yeo N, Dea V, Dorchies P (2003). Gastrointestinal nematodes of cattle in the savannah area of Côte d'Ivoire: an abattoir survey. Rev. Med. Vet. 154:105-112.
 

Anelia TSM, Kamelya KA, Dimitar IV, Jordan AT, Pavletta SD, Magdalena SK, Mitka KM (2006). Anthelmintic activity of some newly synthesized 5(6)-(un) substituted-1H-benzimidazol-2-ylthioacetyl piperazine derivatives. Eur. J. Med. Chem. 41(12):1412-1420.
Crossref
 

Brockwell YM, Elliott TP, Anderson GR, Stanton R, Spithill TW, Sangster NC (2014). Confirmation of Fasciola hepatica resistant to triclabendazole in naturally infected Australian beef and dairy cattle. Int. J. Parasitol. Drugs Drug Resist. 4(1):48-54.
Crossref
 

Diehl MS, Kamanzi AK, Tere H, Betschart B (2004). Prospect of anthelmintic plants in the Ivory Coast using ethnobotanicalcriteria. J. Ethnopharmacol. 95(2-3):277-284.
Crossref
 

Fairweather I (2009). Triclabendazole progress report, 2005-2009: an advancement of learning? J. Helminthol. 83(2):139-50.
Crossref
 

Hussain MA, Dawson CO (2013). Economic Impact of Food Safety Outbreaks on Food Businesses. Foods 2(4):585-589.
Crossref
 

Kaplan RM (2004). Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol. 20(10):477-481.
Crossref
 

Mahiuddin A, David St CB, Naresh K (2007). Synthesis, Reactivity and Biological Activity of Benzimidazoles. Top Heterocycl. Chem. 9:87-118.
Crossref
 

Olaechea F, Lovera V, Larroza M, Raffo F, Cabrera R (2011). Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina). Vet. Parasitol. 178(3-4):364-366.
Crossref
 

Ortiz P, Scarcella S, Cerna C, Rosales C, Cabrera M, Guzmán M, Lamenza P, Solana H (2013). Resistance of Fasciola hepatica against triclabendazole in cattle in Cajamarca (Peru): A clinical trial and an in vivo efficacy test in sheep. Vet. Parasitol. 195(1-2):118-121.
Crossref
 

Phillips MA (1928). The formation of 2-substituted benzimidazoles. J. Chem. Soc.13:2393-2399.
Crossref
 

Roeber F, Jex AR, Gasser RB (2013). Impact of gastrointestinal parasitic nematodes of sheep, and the role of advanced molecular tools for exploring epidemiology and drug resistance - an Australian perspective. Parasit. Vectors 6:153.
Crossref
 

Saunders GI, Wasmuth JD, Beech R, Laing R, Hunt M, Naghra H, Cotton JA, Berriman M, Britton C, Gilleard JS (2013). Characterization and comparative analysis of the complete Haemonchus contortus β-tubulin gene family and implications for benzimidazole resistance in strongylid nematodes. Int. J. Parasitol. 43(6):465-475.
Crossref
 

Tehrani A, Javanbakht J, Jani M, Sasani F, Solati A, Rajabian M, Khadivar F, Akbari H, Mohammadian M (2012). Histopathological Study of Haemonchus contortus in Herrik Sheep Abomasum Aliasghar. J. Bacteriol. Parasitol. 3:5.
Crossref
 

Van Allan JA, Deacon BD (1963). 2-mercaptobenzimidazole. Org. Syntheses 30:50-56.
 

Van den Brom R, Moll L, Borgsteede FHM, Van Doorn DCK, Lievaart-Peterson K, Dercksen DP, Vellema P (2013). Multiple anthelmintic resistance of Haemonchus contortus, including a case of moxidectin resistance, in a Dutch sheep flock. Vet. Record 173:552.
Crossref
 

Winkelhagen AJS, Mank T, de Vries PJ, Soetekouw R (2012). Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg. Infect. Dis. 18(6):1028-1029.
Crossref
 
 
   
 

 




Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 10 No. 33
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES
          */?>